Effect of XlogP and hansen solubility parameters on the prediction of small molecule modified docetaxel, doxorubicin and irinotecan conjugates forming stable nanoparticles

por Xu, Mei-Qi, Zhong, Ting, Yao, Xin, Li, Zhuo-Yue, Li, Hui, Wang, Jing-Ru, Feng, Zhen-Han, Zhang, Xuan
Publicado 2021

Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo

por Xu, Mei-Qi, Hao, Yan-Li, Wang, Jing-Ru, Li, Zhuo-Yue, Li, Hui, Feng, Zhen-Han, Wang, Hui, Wang, Jing-Wen, Zhang, Xuan
Publicado 2021

Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo

por Duan, Xiao-Chuan, Yao, Xin, Zhang, Shuang, Xu, Mei-Qi, Hao, Yan-Li, Li, Zhan-Tao, Zheng, Xiu-Chai, Liu, Man, Li, Zhuo-Yue, Li, Hui, Wang, Jing-Ru, Feng, Zhen-Han, Zhang, Xuan
Publicado 2018

The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death

por Duan, Xiao-Chuan, Peng, Li-Yuan, Yao, Xin, Xu, Mei-Qi, Li, Hui, Zhang, Shuai-Qiang, Li, Zhuo-Yue, Wang, Jing-Ru, Feng, Zhen-Han, Wang, Guang-Xue, Liao, Ai, Chen, Ying, Zhang, Xuan
Publicado 2021

Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid

por Li, Zhuo-Yue, Yin, Yi-Fan, Guo, Yang, Li, Hui, Xu, Mei-Qi, Liu, Man, Wang, Jing-Ru, Feng, Zhen-Han, Duan, Xiao-Chuan, Zhang, Shuang, Zhang, Shuai-Qiang, Wang, Guang-Xue, Liao, Ai, Wang, Shu-Min, Zhang, Xuan
Publicado 2020